For patients whose immune systems have turned against their own peripheral nerves — causing progressive weakness, numbness, and loss of mobility — existing treatments frequently fail. A finding published in Nature Communications raises a compelling possibility: that a cancer-derived immunotherapy tool can rapidly suppress the antibody-producing cells driving nerve destruction, with meaningful functional recovery following.
Teclistamab, a bispecific T-cell engager (BiTE) originally approved for relapsed multiple myeloma, works by simultaneously binding CD3 on T-cells and B-Cell Maturation Antigen (BCMA) on late-stage B-cells and plasma cells, directing T-cell cytotoxicity against antibody factories. In two patients with chronic immune-mediated peripheral nerve myelinopathies refractory to standard care — one with IgM-kappa paraprotein neuropathy, one with anti-MAG antibody neuropathy — teclistamab produced striking results. Pathogenic IgM and anti-MAG antibodies became undetectable within six weeks of the first dose and remained absent throughout follow-up (nine and six months respectively). Both patients showed substantially increased walking distance, reduced nerve swelling on imaging, improved nerve conduction on electroneurography, and declining serum neurofilament light chain levels, a validated biomarker of axonal injury. Nerves previously showing no stimulus response regained detectable activity.
The significance here extends beyond two cases. Depleting BCMA-positive plasma cells is a strategy that has transformed myeloma treatment, but its application to autoimmune neurological disease is genuinely novel and mechanistically logical — plasma cells are the terminal producers of pathogenic antibodies. The observation that serum BCMA re-emerged after an initial drop while antibodies remained suppressed warrants close monitoring in future studies, potentially signaling nascent B-cell repopulation. Critical limitations are obvious: two patients cannot establish efficacy or safety at a population level, adverse event profiles may differ in immunologically distinct neuropathy subtypes, and the durability of remission beyond nine months is unknown. Still, as an off-the-shelf, non-cell-therapy biological, teclistamab's tolerability profile here is encouraging. This should be regarded as hypothesis-generating rather than practice-changing, but it represents a potentially paradigm-shifting pivot for a patient population with few remaining options.